Navigation Links
Ambrx to Present Phase I/II Clinical Data for Optimized, Long Acting Human Growth Hormone Analogue
Date:11/5/2008

SAN DIEGO, Nov. 5 /PRNewswire/ -- Ambrx Inc. today announced the scheduled presentation of data from a Phase I/II clinical trial of ARX201, the company's long-acting human growth hormone (hGH) analogue developed in collaboration with Merck Serono, at the International Congress of Endocrinology meeting in Rio de Janeiro. Andrew R. Hoffman, M.D., Professor of Medicine and Vice President of Academic Affairs at Stanford University, will present the clinical results as part of an oral presentation at 9:30 AM local time (GMT -3 / 7:30 AM EST) on November 12, 2008.

The Phase I/II dose-finding study in adult patients with growth hormone deficiency investigated the safety, tolerability, pharmacokinetic and pharmacodynamic profile of ARX201 following single-dose escalation and repeated dosing. The study analyzed 22 individuals with adult growth hormone deficiency (AGHD). The patients had not received hGH replacement therapy in the six months prior to the study.

ARX201 was administered once weekly by subcutaneous injection. Dosing was titrated based on IGF-I response and/or safety findings. Patients were treated for up to 26 weeks. Clinical measures of body composition were taken at the end of the study period.

About ARX201

ARX201 is a long-acting recombinant human growth hormone drug candidate currently developed by Ambrx and Merck Serono for the treatment of growth hormone deficiencies. ARX201 was generated through a lead optimization process using Ambrx's ReCODE(TM) technology, which effectively enables protein medicinal chemistry. Through this approach, Ambrx was able to generate site specific mono-pegylated hGH molecules that were optimized for potency and time of action. Ambrx believes that ARX201 may have improved pharmacological performance over existing growth hormone products, including the potential for less frequent dosing.

In pre-clinical studies, ARX201 met or exceeded key end points in assays that are believed to be pred
'/>"/>

SOURCE Ambrx Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Ambrx Appoints Douglas Axelrod Senior Vice President for Clinical Research and Development
2. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
3. Avicena Group to Present at Noble Financial Conference
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
6. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
7. CEL-SCI to Present at the Noble Financial Conference
8. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
9. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
10. Strategic Diagnostics Updates Roth Conference Presentation Time
11. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)... Intarcia Therapeutics, Inc. deliv...S® continuous delivery of exenatide) program ...Annual Diabetes Technology Meeting in San Francisc...n/prnh/20050301/SFTU126LOGO ) ,, Continuous S...ers Plasma Glucose, HbA1c and Reduces Weight in a ...
(Date:11/5/2009)... 5 GenVec, Inc. (Nasdaq:... the third quarter ended September 30, 2009. GenVe...hare) for the three months ended September 30, 200...r share) in the comparable quarter of 2008. For th...et loss was $14.1 million ($0.15 per share), compa...
(Date:11/5/2009)...wswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulleti...er, President and CEO of Imagenetix, will be prese...RO Conference on Thursday, December 3rd, at 10:30 ...out LD MICRO ,, LD MICRO is a by-invitation onl...ued companies in the micro-cap space. Since 2002, ...
(Date:11/5/2009)...Newswire-FirstCall/ -- Transgenomic, Inc. (OTC Bul...ts for the quarter ended September 30, 2009. The C...bles that follow. ,, Third Quarter 2009 ,,....01 per share for the third quarter of 2009 as com... for the third quarter of 2008. ,, Net sales w...
Breaking Biology Technology:Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7
...Pa., May 18 ViroPharma Incorporated (Nasdaq: VP...ional Organization for Rare Disorders (NORD) Annua...terase inhibitor (human)) to market for a rare and...E). , , HAE is a rare, severely debilitating, lif...ncy of C1 inhibitor, a human plasma protein. Patie...
...gazine Pays Tribute to America,s Top Research Scie...air of Prana,s Biotechnology Research & Develo...May 18 Dr. Rudy Tanzi, Prana Biotechnology,s (Nas...tor of the Genetics and Aging Research Unit at the...ses , will be featured in a six-page photo spread...
... Will be Reported from Phase 2 Studies Evaluating ...tal Cancer and Gastrointestinal Stromal Tumors (GI...ls, Inc. (Nasdaq: KERX ) today announced that fo...,s Akt-inhibitor for cancer, were accepted for pre...he 45th Annual Meeting of the American Society of ...
Other Biology Technology:ViroPharma Incorporated Honored by the National Organization for Rare Disorders 2ViroPharma Incorporated Honored by the National Organization for Rare Disorders 3ViroPharma Incorporated Honored by the National Organization for Rare Disorders 4ViroPharma Incorporated Honored by the National Organization for Rare Disorders 5ROCK STARS OF SCIENCE: Prana's Co-Founding Scientist, Rudy Tanzi Teams up with Star-Powered Cast in GQ Photoshoot 2ROCK STARS OF SCIENCE: Prana's Co-Founding Scientist, Rudy Tanzi Teams up with Star-Powered Cast in GQ Photoshoot 3Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology 2Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology 3Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology 4
(Date:11/4/2009)...- Lowly bacteria, it turns out, hold the power to ... around the world clean up toxic waste on test sit...y RDX, were invented back in World War II and have...se high-energy compounds are often used to propel ...f TNT. , But with increased knowledge of their...
(Date:11/4/2009)....J., Oct. 20 Quest Diagn...ding provider of diagnostic testing, information a...ended September 30, 2009, income from continuing o...ed share, from $160 million, or $0.81 per diluted ...rd quarter results were reduced by a $0.03 per sha...
(Date:11/4/2009)...Calif., Oct. 23 GenVault Corporati...nagement for genomic discovery, medicine and ident...., GenVault,s President and CEO, will be presentin...n October 26th and 27th in La Jolla, CA. ,, Dur...verview of the company together with recent custom...
Breaking Biology News(10 mins):Genomic research will enable greener cleanup of military explosive test sites 2Quest Diagnostics Reports Strong Performance in Third Quarter 2009 2Quest Diagnostics Reports Strong Performance in Third Quarter 2009 3Quest Diagnostics Reports Strong Performance in Third Quarter 2009 4Quest Diagnostics Reports Strong Performance in Third Quarter 2009 5Quest Diagnostics Reports Strong Performance in Third Quarter 2009 6Quest Diagnostics Reports Strong Performance in Third Quarter 2009 7Quest Diagnostics Reports Strong Performance in Third Quarter 2009 8Quest Diagnostics Reports Strong Performance in Third Quarter 2009 9Quest Diagnostics Reports Strong Performance in Third Quarter 2009 10Quest Diagnostics Reports Strong Performance in Third Quarter 2009 11Quest Diagnostics Reports Strong Performance in Third Quarter 2009 12Quest Diagnostics Reports Strong Performance in Third Quarter 2009 13Quest Diagnostics Reports Strong Performance in Third Quarter 2009 14Quest Diagnostics Reports Strong Performance in Third Quarter 2009 15Quest Diagnostics Reports Strong Performance in Third Quarter 2009 16Quest Diagnostics Reports Strong Performance in Third Quarter 2009 17GenVault Corporation to Present at the 2009 BIOCOM Investor Conference 2Prebiotics Add Heart Health Bone Health and Digestive Health Support to Research Proven Cancer Fighting Ability 58335 1Prebiotics Add Heart Health Bone Health and Digestive Health Support to Research Proven Cancer Fighting Ability 58335 2synergIT Presents at VMworld 2009 in San Francisco 58333 1synergIT Presents at VMworld 2009 in San Francisco 58333 2synergIT Presents at VMworld 2009 in San Francisco 58333 3RCRC Independent Review Board Announces DHHS Research Oversight 58331 1RCRC Independent Review Board Announces DHHS Research Oversight 58331 2
...ve hair-like protrusions with a sticky protein on ...ed, bungee cord-like structure of the protrusions ...gh fluid flow inside the body, researchers report ...hers at the University of Washington in Seattle an... the bacterium E. coli attaches to mucous membrane...
...h shows that a chemical compound found in many air...ther deodorizing products, may be harmful to the l...titute of Environmental Health Sciences (NIEHS), a...that exposure to a volatile organic compound (VOC)...odest reductions in lung function. , "Even a small...
... microorganisms manage to exist and even thrive in...ot springs? A team of scientists from the Weizmann...f. Avigdor Scherz, has found that a switch in just...can make a difference between functioning best at ...in extreme heat. The results of their research, wh...
Other Biology News:Tiny shock absorbers help bacteria stick around inside the body 2Chemical in many air fresheners may reduce lung function 2Chemical in many air fresheners may reduce lung function 3Bacteria beat the heat 2
...nal [6331] to Salmonella typhimurium The genus Sa...eae. The genus is composed of Gram-negative bacill...Salmonellae possess 3 major antigens; the "H" or f... antigen (part of the LPS moiety) and the "Vi" or ...
...W4 liquid handling system from Molecular Devices p...l in one instrument. The system handles a variety ...6-, 384- and 1536-welland is the first to handle 1...optimized to dispense from four different channels...
...sodium pyruvate, 50 mg/L streptomycin sulfate, 100...lcium chloride, and magnesium chloride. The use of...is generally attributed to early workers in the fi...f inorganic salts designed to maintain contractili...
Horizontal Laminar Flow Work Station from Terra Universal, Inc.
Biology Products: